AR111914A1 - TREM2 ANTIGENS BINDING PROTEINS AND USES OF THEM - Google Patents
TREM2 ANTIGENS BINDING PROTEINS AND USES OF THEMInfo
- Publication number
- AR111914A1 AR111914A1 ARP180101034A ARP180101034A AR111914A1 AR 111914 A1 AR111914 A1 AR 111914A1 AR P180101034 A ARP180101034 A AR P180101034A AR P180101034 A ARP180101034 A AR P180101034A AR 111914 A1 AR111914 A1 AR 111914A1
- Authority
- AR
- Argentina
- Prior art keywords
- antigen
- trem2
- binding proteins
- absence
- agonist
- Prior art date
Links
Abstract
La presente se refiere a proteínas de unión a antígenos, tales como anticuerpos monoclonales, que se unen específicamente y activan, el receptor de activación humano expresado en células mieloides 2 (TREM2) y composiciones farmacéuticas que comprenden dichas proteínas de unión a antígenos. Las proteínas de unión a antígenos agonistas (por ejemplo, anticuerpos) son capaces de activar la señalización de TREM2 / DAP12 en células mieloides en ausencia de reticulación mediada por Fc de las proteínas de unión a antígenos. También se describen métodos para tratar o prevenir afecciones asociadas a la pérdida de función de TREM2, tales como la enfermedad de Alzheimer y la esclerosis múltiple, mediante el uso de proteínas de unión a antígenos. Reivindicación 1: Una proteína de unión a antígenos agonista aislada que se une específicamente a TREM2 humano, donde la proteína de unión a antígenos agonista aumenta los niveles de pSyk mediados por TREM2 humano con una EC₅₀ menor que 500 pM en ausencia de un agente de reticulación, según se mide mediante un ensayo de pSyk basado en células.This relates to antigen-binding proteins, such as monoclonal antibodies, that specifically bind and activate, the human activation receptor expressed on myeloid cells 2 (TREM2), and pharmaceutical compositions comprising such antigen-binding proteins. Agonist antigen-binding proteins (eg, antibodies) are capable of activating TREM2 / DAP12 signaling in myeloid cells in the absence of Fc-mediated cross-linking of antigen-binding proteins. Also disclosed are methods of treating or preventing conditions associated with loss of TREM2 function, such as Alzheimer's disease and multiple sclerosis, through the use of antigen-binding proteins. Claim 1: An isolated agonist antigen-binding protein that specifically binds human TREM2, wherein the agonist antigen-binding protein increases human TREM2-mediated pSyk levels with an EC₅₀ of less than 500 pM in the absence of a cross-linking agent , as measured by a cell-based pSyk assay.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762488691P | 2017-04-21 | 2017-04-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR111914A1 true AR111914A1 (en) | 2019-09-04 |
Family
ID=68069932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180101034A AR111914A1 (en) | 2017-04-21 | 2018-04-23 | TREM2 ANTIGENS BINDING PROTEINS AND USES OF THEM |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR111914A1 (en) |
-
2018
- 2018-04-23 AR ARP180101034A patent/AR111914A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019012998A2 (en) | Trem2 antigen-binding proteins and uses of these | |
| CL2017002244A1 (en) | Specific bispecific antibodies for fap and dr5, specific antibodies for dr5 and methods of use. (divisional application 2829-2015). | |
| MX2020004129A (en) | Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies. | |
| BR112018008442A2 (en) | chimeric receptors containing traf inducer domains and related compositions and methods | |
| AR107781A1 (en) | BISPECIFIC MOLECULES THAT HAVE IMMUNORREACTIVITY WITH PD-1 AND CTLA-4, AND METHODS OF USE OF THE SAME | |
| PE20191813A1 (en) | ANTI-ILT4 ANTIBODIES AND ANTIGEN BINDING FRAGMENTS | |
| CL2021000517A1 (en) | Labeled antibody and / or fragment thereof comprising a monoclonal antibody or a fragment thereof, which specifically binds human tau; nucleic acid that encodes it; vector; cell; method of producing antibody; and use of the same to inhibit the aggregation of tau, and associated diseases (divisional application no. 202001003) | |
| EA201792221A1 (en) | ANTIBODIES AGAINST SORTILINE AND METHODS OF THEIR APPLICATION | |
| CR20180480A (en) | CHEMICAL RECEPTORS AND METHODS OF USE OF THE SAME | |
| CL2020001619A1 (en) | Anti-cd33 antibodies and methods of using them. (divisional request 201903095) | |
| PE20200152A1 (en) | ENHANCED ANTIGEN BINDING RECEPTORS | |
| CL2019001434A1 (en) | Antigen-binding proteins that bind to the leptin receptor. (divisional application 201800946) | |
| BR112017003582A2 (en) | antibodies, compositions and uses | |
| BR112016013347A2 (en) | anti-il-33 neutralizing human monoclonal antibody | |
| CL2019001324A1 (en) | Anti-met antibodies, bispecific antigen-binding molecules that bind to met, and methods of using the same. | |
| ECSP21010450A (en) | ANTI-SORTILINA ANTIBODIES AND METHODS FOR THEIR USE | |
| UA118029C2 (en) | Human fcrn-binding modified antibodies and methods of use | |
| BR112019008351A2 (en) | immunoglobulins and their uses | |
| PE20140673A1 (en) | NEW MODULATORS AND METHODS FOR THEIR USE | |
| CL2018003608A1 (en) | Isolated antibody or antigen binding fragment thereof that specifically binds interleukin-25 hjumana (il-2525); pharmaceutical composition comprising it; use of said pharmaceutical composition to treat a disease or disorder associated with the activity or expression of il-25. (divisional application 201700703) | |
| UY38407A (en) | TREM2 STABILIZING ANTIBODIES | |
| WO2017066481A8 (en) | Chimeric antigen receptors containing a chlorotoxin domain | |
| BR112020009759A8 (en) | SPECIFIC ANTIBODIES FOR IMMUNOGLOBULIN-LIKE TRANSCRIPT 3 (ILT3) AND USES THEREOF | |
| CO2018012497A2 (en) | Interferon beta antibodies and uses thereof | |
| AR111914A1 (en) | TREM2 ANTIGENS BINDING PROTEINS AND USES OF THEM |